NeuroMetrix, Inc. (NURO): Price and Financial Metrics

NeuroMetrix, Inc. (NURO): $1.01

-0.04 (-3.81%)

POWR Rating

Component Grades








Add NURO to Watchlist
Sign Up

Industry: Biotech




#233 of 382

in industry

NURO Price/Volume Stats

Current price $1.01 52-week high $4.73
Prev. close $1.05 52-week low $0.93
Day low $0.96 Volume 1,501,800
Day high $1.21 Avg. volume 57,774
50-day MA $1.27 Dividend yield N/A
200-day MA $1.89 Market Cap 7.92M

NURO Stock Price Chart Interactive Chart >

NURO Stock Summary

  • NURO has a market capitalization of $8,545,108 -- more than approximately only 3.57% of US stocks.
  • The ratio of debt to operating expenses for NEUROMETRIX INC is higher than it is for about merely 8.04% of US stocks.
  • NURO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 8.02% of US stocks.
  • Stocks that are quantitatively similar to NURO, based on their financial statements, market capitalization, and price volatility, are AMST, HSTO, CTSO, YY, and IRBT.
  • Visit NURO's SEC page to see the company's official filings. To visit the company's web site, go to

NURO Valuation Summary

  • NURO's price/earnings ratio is -1.6; this is 106.64% lower than that of the median Healthcare stock.
  • Over the past 229 months, NURO's price/sales ratio has gone down 6.2.

Below are key valuation metrics over time for NURO.

Stock Date P/S P/B P/E EV/EBIT
NURO 2023-05-23 1.1 0.4 -1.6 -1.2
NURO 2023-05-22 1.1 0.4 -1.7 -1.3
NURO 2023-05-19 1.0 0.4 -1.6 -1.2
NURO 2023-05-18 1.0 0.4 -1.6 -1.2
NURO 2023-05-17 1.0 0.3 -1.5 -1.1
NURO 2023-05-16 1.0 0.3 -1.5 -1.1

NURO Growth Metrics

    The year over year net cashflow from operations growth rate now stands at -107.88%.
  • Its 4 year net cashflow from operations growth rate is now at 67.57%.
  • The 3 year cash and equivalents growth rate now stands at 230.09%.
Over the past 49 months, NURO's revenue has gone down $9,061,955.

The table below shows NURO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 8.228858 -4.318874 -4.72774
2022-06-30 8.325214 -3.083638 -3.808575
2022-03-31 8.400412 -2.780285 -3.180236
2021-12-31 8.253493 -2.073694 -2.281457
2021-09-30 8.243062 -1.280035 -1.604223
2021-06-30 8.214931 -0.803839 -1.174247

NURO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NURO has a Quality Grade of D, ranking ahead of 21.62% of graded US stocks.
  • NURO's asset turnover comes in at 0.625 -- ranking 66th of 186 Medical Equipment stocks.
  • BLFS, NVNO, and ZYXI are the stocks whose asset turnover ratios are most correlated with NURO.

The table below shows NURO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.625 0.729 -0.970
2021-06-30 0.944 0.739 -0.690
2021-03-31 0.902 0.717 -0.828
2020-12-31 0.948 0.712 -1.087
2020-09-30 0.969 0.684 -1.415
2020-06-30 0.970 0.635 -1.936

NeuroMetrix, Inc. (NURO) Company Bio

NeuroMetrix Inc. is a medical device company that designs, develops and sells proprietary products used to diagnose neuropathies. The Company's neuropathy diagnostic system provides primary care and specialist physicians objective information that aids in the diagnosis of neuropathies at the point of service.

NURO Latest News Stream

Event/Time News Detail
Loading, please wait...

NURO Latest Social Stream

Loading social stream, please wait...

View Full NURO Social Stream

Latest NURO News From Around the Web

Below are the latest news stories about NEUROMETRIX INC that investors may wish to consider to help them evaluate NURO as an investment opportunity.

Q1 2023 NeuroMetrix Inc Earnings Call

Q1 2023 NeuroMetrix Inc Earnings Call

Yahoo | May 4, 2023

NeuroMetrix Reports Q1 2023 Financial Results

WOBURN, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2023. The Company’s mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices. Q1 Highlights: Q1 2023 revenue was $1.7 million, a decrease of 25.1% from $2.3M in the first quarter of 2022. The primary reason was that DPNCheck® sale

Yahoo | May 3, 2023

NeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference Call

WOBURN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2023 first quarter financial results before the opening of the market on May 3, 2023. The Company will host a conference call at 8:00 a.m., Eastern Time on May 3, 2023 to discuss its financial results as well as business developments affecting the Company. For participants who wish to access the Earnings Call live via telephone and be able to ask questions, please registe

Yahoo | April 28, 2023

NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting

WOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39th Annual Meeting on March 23 - 26 in Ft. Lauderdale, FL. In addition, two scientific posters reporting new data on the use of Quell in patients with fibromyalgia will be presented. Fibromyalgia is a chronic condition characterized by generalized pain, fatigue, poor sleep, memory and concentration impairments, mood disorders and other disab

Yahoo | March 21, 2023

NeuroMetrix Full Year 2022 Earnings: US$0.62 loss per share (vs US$0.45 loss in FY 2021)

NeuroMetrix ( NASDAQ:NURO ) Full Year 2022 Results Key Financial Results Revenue: US$8.26m (flat on FY 2021). Net loss...

Yahoo | February 25, 2023

Read More 'NURO' Stories Here

NURO Price Returns

1-mo -27.34%
3-mo -44.20%
6-mo -42.94%
1-year -76.01%
3-year -52.80%
5-year -92.41%
YTD -32.21%
2022 -70.32%
2021 58.86%
2020 -26.51%
2019 -43.42%
2018 -56.04%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!